IL123441A - Quantitation of p97 to diagnose and monitor alzheimer's disease - Google Patents

Quantitation of p97 to diagnose and monitor alzheimer's disease

Info

Publication number
IL123441A
IL123441A IL12344196A IL12344196A IL123441A IL 123441 A IL123441 A IL 123441A IL 12344196 A IL12344196 A IL 12344196A IL 12344196 A IL12344196 A IL 12344196A IL 123441 A IL123441 A IL 123441A
Authority
IL
Israel
Prior art keywords
disease
quantitation
diagnose
alzheimer
treatment
Prior art date
Application number
IL12344196A
Other languages
English (en)
Other versions
IL123441A0 (en
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of IL123441A0 publication Critical patent/IL123441A0/xx
Publication of IL123441A publication Critical patent/IL123441A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
IL12344196A 1995-08-31 1996-08-30 Quantitation of p97 to diagnose and monitor alzheimer's disease IL123441A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/520,933 US5981194A (en) 1992-07-10 1995-08-31 Use of p97 and iron binding proteins as diagnostic and therapeutic agents
PCT/CA1996/000587 WO1997008560A1 (en) 1995-08-31 1996-08-30 QUANTITATION OF p97 TO DIAGNOSE AND MONITOR ALZHEIMER'S DISEASE

Publications (2)

Publication Number Publication Date
IL123441A0 IL123441A0 (en) 1998-09-24
IL123441A true IL123441A (en) 2001-01-11

Family

ID=24074638

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12344196A IL123441A (en) 1995-08-31 1996-08-30 Quantitation of p97 to diagnose and monitor alzheimer's disease

Country Status (11)

Country Link
US (3) US5981194A (de)
EP (1) EP0847530B1 (de)
JP (1) JP3259963B2 (de)
CN (1) CN1198214A (de)
AT (1) ATE269545T1 (de)
AU (1) AU717198B2 (de)
CA (1) CA2230372C (de)
DE (1) DE69632734T2 (de)
IL (1) IL123441A (de)
NZ (1) NZ315997A (de)
WO (1) WO1997008560A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905817B1 (en) * 1998-10-01 2005-06-14 Licestia Ltd. Ret-independent signaling pathway for GDNF
JP4414023B2 (ja) * 1999-08-05 2010-02-10 オリエンタル酵母工業株式会社 関節炎関連メラノトランスフェリンの測定方法および試薬
US6586239B1 (en) * 2000-01-07 2003-07-01 Agy Therapeutics, Inc. Purifying microglial cells by binding cell Fc receptor to immunoglobulin G Fc domain
JP2003525038A (ja) * 2000-02-08 2003-08-26 ユニバーシティー オブ ブリティッシュ コロンビア 治療薬をスクリーニングするための組成物および方法
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
ATE355374T1 (de) * 2000-11-27 2006-03-15 Praecis Pharm Inc Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
AU2002322720B2 (en) * 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US8129504B2 (en) * 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2004043218A2 (en) 2002-11-14 2004-05-27 Brainsgate Ltd. Surgical tools and techniques for stimulation
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
JP2005537266A (ja) * 2002-07-12 2005-12-08 バイオマリン ファーマシューティカル インコーポレイテッド 加水分解性活性物質であるバイオポリマーコンジュゲートを作製するためのイソシアネートリンカーの使用
US7354750B2 (en) * 2002-10-18 2008-04-08 Promega Corporation Methods for separating molecules
US7919103B2 (en) * 2003-05-09 2011-04-05 Transfert Plus Compound and method for regulating plasminogen activation and cell migration
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
EP1730174B1 (de) * 2004-03-05 2010-04-21 The Board Of Trustees Of The University Of Illinois Peptidträger für die verabreichung von arzneimitteln
EP2099523A2 (de) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Verfahren zur behandlung von pompe-krankheit
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
JP2011516419A (ja) * 2008-03-28 2011-05-26 カイナ エルエルシー 鉄欠乏性障害を治療するためのフェリチンの使用
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
EP3679942A1 (de) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
CN103747807B (zh) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97‑抗体缀合物和使用方法
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
CA3140358A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP2878335B1 (de) 2013-11-10 2018-01-03 Brainsgate Ltd. Implantat und implantationssystem für nervenstimulator
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
AU2015252906C1 (en) 2014-05-01 2020-09-17 Bioasis Technologies Inc. p97-polynucleotide conjugates
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11752315B1 (en) 2016-10-07 2023-09-12 Carlos A. Hakim Method of treating normal pressure hydrocephalus
US10473672B2 (en) * 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
CN113430146B (zh) * 2021-07-28 2023-03-17 西安医学院 表达石杉碱甲的苏云金芽孢杆菌hw1株及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
GB2188637B (en) * 1986-02-07 1990-11-14 Oncogen Vaccines against melanoma
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
AU4553793A (en) * 1992-07-10 1994-01-31 University Of British Columbia, The Use of p97 and iron binding proteins as diagnostic and therapeutic agents

Also Published As

Publication number Publication date
NZ315997A (en) 1999-08-30
US6455494B1 (en) 2002-09-24
CA2230372C (en) 2008-04-29
AU717198B2 (en) 2000-03-23
US5981194A (en) 1999-11-09
CN1198214A (zh) 1998-11-04
DE69632734D1 (de) 2004-07-22
IL123441A0 (en) 1998-09-24
DE69632734T2 (de) 2005-06-30
EP0847530B1 (de) 2004-06-16
AU6783496A (en) 1997-03-19
JPH11511257A (ja) 1999-09-28
WO1997008560A1 (en) 1997-03-06
CA2230372A1 (en) 1997-03-06
US20030077693A1 (en) 2003-04-24
JP3259963B2 (ja) 2002-02-25
EP0847530A1 (de) 1998-06-17
ATE269545T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
IL123441A0 (en) Quantitation of p97 to diagnose and monitor alzheimer's disease
CA2139862A1 (en) Use of p97 and iron binding proteins as diagnostic and therapeutic agents
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HU9502065D0 (en) Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes
ID28003A (id) Turunan-turunan adamantana
WO2003009815A3 (en) Compositions and methods for modulating blood-brain barrier transport
FI972287L (fi) Uudenlaisia polysubstituoituja DTPA-johdoksia ja niiden metallikomplekseja, kyseisiä komplekseja sisältäviä farmaseuttisia aineita, niiden käyttö diagnosoinnissa ja terapiassa sekä menetelmiä kyseisten kompleksinmuodostajien ja kompleksien valmistamiseksi ja menetelmiä kyseisten.
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
IL141507A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
Achamallah et al. Mania induced by fluoxetine in an adolescent patient.
GEP20043267B (en) Adenosine Receptor Antagonists, Methods of Making and Using the Same
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
Forster et al. Fluoxetine for premature ejaculation.
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
Phillips A possible paroxetine withdrawal syndrome.
CA2069638A1 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
EP1152762B8 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
MY122477A (en) Sertraline oral concentrate
BG106151A (en) Pharmaceutical complex
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
EP0666745A4 (de) Diagnose und therapie der parkinson-krankheit.
CA2208630A1 (en) 4-amino-2-ureidopyrimidine-5-carboxamides, processes for their preparation, pharmaceuticals comprising these compounds, and their use
GB9209599D0 (en) Novel therapy for the treatment of parkinsons disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired